Posts in January 2020

Colorectal cancer models for novel drug discovery.

Golovko D, Kedrin D, Yilmaz ÖH, Roper J*. Colorectal cancer models for novel drug discovery. Expert Opin Drug Discov. 2015;10(11):1217–29. […]
by Jatin Roper
on Jan 5
Read more

Resistance to dual blockade of the kinases PI3K and mTOR in KRAS-mutant colorectal cancer models results in combined sensitivity to inhibition of the receptor tyrosine kinase EGFR.

Belmont PJ, Jiang P, McKee TD, Xie T, Isaacson J, Baryla NE, Roper J, Sinnamon MJ, Lee NV, Kan JL, […]
by Jatin Roper
on Jan 5
Read more

Co-occurrence of idiopathic granulomatous hepatitis and primary biliary cirrhosis.

Paul S, Sepehr GJ, Weinstein B, RoperJ. Co-occurrence of idiopathic granulomatous hepatitis and primary biliary cirrhosis. Dig Dis Sci. 2014 […]
by Jatin Roper
on Jan 5
Read more

Overview of genetically engineered mouse models of colorectal carcinoma to enable translational biology and drug development.

RoperJ, Martin ES, Hung KE. Overview of genetically engineered mouse models of colorectal carcinoma to enable translational biology and drug […]
by Jatin Roper
on Jan 5
Read more

Cross-species analysis of genetically engineered mouse models of MAPK-driven colorectal cancer identifies hallmarks of the human disease.

Belmont PJ, Budinska E, Jiang P, Sinnamon MJ, Coffee E, Roper J, Xie T, Rejto PA, Derkits S, Sansom OJ, […]
by Jatin Roper
on Jan 5
Read more

Combination PI3K/MEK inhibition promotes tumor apoptosis and regression in PIK3CA wild-type, KRAS mutant colorectal cancer.

RoperJ, Sinnamon MJ, Coffee EM, Belmont P, Keung L, Georgeon-Richard L, Wang WV, Faber AC, Yun J, Yilmaz ÖH, Bronson […]
by Jatin Roper
on Jan 5
Read more

RAF mutations to BCL-2/BCL-XL inhibition by suppressing MCL-1.

Faber AC, Coffee EM, Costa C, Dastur A, Ebi H, Hata AN, Yeo AT, Edelman EJ, Song Y, Tam AT, […]
by Jatin Roper
on Jan 5
Read more

Concomitant BRAF and PI3K/mTOR blockade is required for effective treatment of BRAF(V600E) colorectal cancer.

Coffee EM, Faber AC, Roper J, Sinnamon MJ, Goel G, Keung L, Wang WV, Vecchione L, de Vriendt V, Weinstein […]
by Jatin Roper
on Jan 3
Read more

Development of a colon cancer GEMM-derived orthotopic transplant model for drug discovery and validation.

Martin ES, Belmont PJ, Sinnamon MJ, Richard LG, Yuan J, Coffee EM, Roper J, Lee L, Heidari P, Lunt SY, […]
by Jatin Roper
on Jan 3
Read more

Priceless GEMMs: genetically engineered mouse models for colorectal cancer drug development.

RoperJ, Hung KE. Priceless GEMMs: genetically engineered mouse models for colorectal cancer drug development. Trends Pharmacol Sci. 2012 Aug;33(8):449–55. PMID: […]
by Jatin Roper
on Jan 3
Read more
Categories